Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand
February 11th 2020
Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.